Both in Pharmaceuticals
CytomX Therapeutics vs Evolus
Over the past year CTMX returned −43.6% and EOLS returned +13.8%; their daily moves had a correlation of 0.26.
CTMX −43.6% EOLS +13.8%Growth of $1, one year, split-adjusted
| Metric | CTMX | EOLS |
|---|---|---|
| Price | $2.22 | $7.27 |
| Market cap | $482.6M | $480.2M |
| Today | −0.67% | +1.54% |
| 1 month | −14.1% | −2.7% |
| 6 months | −45.7% | +14.1% |
| Year to date | −48.0% | +9.3% |
| 1 year | −38.0% | +12.5% |
| Revenue growth (YoY) | −92.4% | +21.2% |
| Gross margin | 100.0% | 68.0% |
| Net margin | −1457.4% | −9.6% |
| P/E (TTM) | — | — |
| Price / sales | 26.4× | 1.5× |
| Net cash | $330.3M | -$141.9M |
| Dividend yield | — | — |
| Volatility (60d) | 67.5% | 52.5% |
| Short % of float | 21.4% | 12.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).